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Development of an effective male contraceptive agent remains a challenge. The present
study evaluates the potential of N, N-Dimethylacetamide (DMA), a FDA approved
excipient as a male contraceptive agent. Male Sprague Dawley rats injected with DMA
for a period of 8 weeks (one injection per week) showed a significant alteration of
reproductive parameters. Furthermore, DMA treated animals showed complete infertility
in a dose dependent manner, as no pups were born despite proper mating between
females and DMA treated males. However, stopping the DMA treatment for a period
of 8 weeks (after the initial treatment) restored the reproductive parameters to normal.
Moreover, the fertility was resumed to normal as pups were born in the groups where
DMA treatment was halted after initial DMA treatment. All these changes had no effect
on the level of reproductive hormones FSH, LH and testosterone. Taken together, our
results indicate that DMA acts in a reversible and non-hormonal manner to achieve
contraception in rats. Therefore, repurposing the use of DMA could lead in a short time
to an inexpensive and safer male contraceptive option.
Keywords: male contraception, bromodomain (BRD), reproduction, excipient, rat, BET inhibitor
INTRODUCTION
The rate of unwanted pregnancies is globally increasing. About 40% of all pregnancies were
unintended in 2012 (Sedgh et al., 2014). This high rate is due to barriers for women to access
contraceptives and insufficient knowledge of available contraceptive methods. Certain fraction
of women who take the female contraceptive pills have to quit it due to development of high
risk of venous thromboembolism, breast cancer and other side effects (McDaid et al., 2017).
Another major and often neglected reason leading to unintended pregnancies is the lack of
a reliable male contraceptive method (Plana, 2017), leaving couples with limited contraceptive
options. No successful male contraceptive agent or method has been developed since condoms
in the 18th century and vasectomy in the 19th century (Drake et al., 1999; Khan et al., 2013).
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A certain proportion of men face difficulties while using condoms
as use of latex condoms can lead to allergic reactions and skin
irritation. For some men the use of condoms is associated with
a decrease in sexual pleasure (Newby et al., 2013; Caminati
et al., 2019). Vasectomy, by contrast, requires a surgery under
local anesthesia where the vas deference is surgically interrupted
bilaterally through a small incision in the scrotum. This is
the best choice for couples who do not want further children.
Although the process is surgically reversible, the pregnancy
rates after reversal vary from 50–75% depending on the time
between the vasectomy and the reversal surgery (Belker et al.,
1991; Heidenreich et al., 1994). Therefore, vasectomy cannot
be labeled as a reliable reversible contraceptive method and
an urgent need for a potent, reliable and reversible male
contraceptive agent persists.
The sensitivity of the spermatogenesis process to hormonal
regulation was long believed to be a promising route for the
development of a male contraceptive (Wang and Swerdloff,
2010). To this end, Testosterone and its analogs have been
injected to signal the hypothalamus to stop producing
GnRH and thus inhibiting intra testicular testosterone
release. Even though this approach reduces sperm counts,
the method was never 100% effective (Contraceptive efficacy
of testosterone-induced azoospermia in normal men. World
Health Organization Task Force on methods for the regulation of
male fertility, 1990). Although many novel hormonal molecules
are in clinical trials, other non-endocrine approaches are
also considered and would be more favorable (Thirumalai
and Page, 2019). Multiple genes and proteins involved
in sperm production and transport are attractive targets.
If the function of any of these genes or proteins could
be blocked, it would become a potential target for male
contraception purposes.
In recent years, several inhibitors for Bromodomain and
Extra-Terminal motif (BET) proteins were synthesized and their
epigenetic activities on diverse tissues analyzed in depth. The
BET family of bromodomain proteins include BRD2, BRD3,
BRD4, and BRDT, which are expressed at distinct stages during
spermatogenesis (Berkovits andWolgemuth, 2013). It was shown
that inhibition of BRDT by small BET inhibitor JQ1 leads to
reversible contraception in male mice (Matzuk et al., 2012). N,
N-Dimethylacetamide (DMA), an FDA approved solvent, acts
as a low affinity inhibitor for BRD2 and BRD4 (Ghayor et al.,
2017). N, N-Dimethylacetamide is a widely used pharmaceutical
agent, regularly injected in humans as a solvent facilitating the
application of insoluble drugs (Hassan, 1999; Hempel et al.,
2007). Ideally, an excipient should not possess any biological
activity. However, in a recent study, we have shown that DMA
affects spermatogenesis and leads to infertility by acting non-
hormonally and post-meiotically (Khera et al., 2020).
In the current study, we examined the effects of DMA
treatment on spermatogenesis and infertility in vivo with
emphasis on a possible recovery once the treatment is halted.
Since the process of spermatogenesis is conserved over species,
results from our rat model could be indicative for a possible use of
DMA as a non-hormonal, post meiotically acting and reversible
male contraceptive in humans.
MATERIALS AND METHODS
Animals Experiments
All animal procedures were according to the ARRIVE guidelines
approved by the Animal Ethics Committee of the local authorities
(Veterinäramt, Canton Zurich, project codes: 40/2012 (approved
on the April 2, 2012) and 068/2015 (approved on the July 31,
2015), and follow the EUDirective 2010/63/EU for animals. Male
SpragueDawley rats (age: 6 weeks old) were ordered fromCharles
River Laboratories. Three animals were pooled in one cage and
were acclimatized to the animal facility environment for a period
of two weeks. After two weeks, each of the animals were weighed
and randomized. The animals were divided into two groups:
PBS group and the DMA treated group. They were injected as
previously described (Khera et al., 2020). Volume of DMA to be
injected was one third of the LD50 (862 mg/kg) (Bartsch et al.,
1976). This dose was found to be effective in our previous studies
of DMA on rats (Ghayor et al., 2017). Animals were injected once
per week, intra-peritoneally for eight consecutive weeks, which
is equivalent to one spermatogenesis cycle in rats. In addition,
a pilot study with n = 3 showed a significant decrease in sperm
count and alteration of seminiferous epithelium (data not shown)
after 8 weeks (one injection per week), therefore the chosen dose
was continued. At the end of 8 weeks, the treatment was stopped
for another 8 weeks. The animals were analyzed three times
weekly for any abnormalities. At the end of a total of 16 weeks
(8 weeks of DMA/PBS treatment plus 8 weeks of stopping the
treatment) the animals were sacrificed, and their reproductive
parameters were analyzed.
For the breeding experiments, one male was mated with one
female and the pups were analyzed at subsequent time intervals
(explained in detail in results section).
Hematoxylin and Eosin Staining
The testis and epididymis were collected in bouin’s solution. Liver
was collected in formalin. Histological sections and Hematoxylin
and eosin (H&E) stained slides were performed as previously
described (Khera et al., 2020). The sections were analyzed blindly
by two independent experimenters.
Measurement of Area of Seminiferous
Tubules
Hematoxylin and eosin stained testis slides were used to calculate
the area of seminiferous tubules. For each sample the area
of twenty seminiferous tubules was randomly calculated using
ImageJ software.
qPCR Analysis
RNA was extracted using TRIzol reagent (Invitrogen) and
reverse transcribed into cDNA using iScript reverse transcription
supermix (Bio-Rad). RT-qPCR was performed using gene-
specific primers (Supplementary Table) with SsoAdvanced
universal SYBR green supermix and the CFX Connect real-time
system (Bio-Rad) using beta actin as the housekeeping gene.
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Computer Assisted Sperm Analysis
The left epididymis was collected in HTF medium (Irvine
Scientific, Article number 90126). Caudal epididymis was
carefully cut and punctured using a syringe needle. It was then
incubated in pre warmed HTF medium for 10 min at 37◦C.
The spermatozoa were allowed to swim out in the medium and
then collected in a 1.5 mL Eppendorf tube. A Computer Assisted
SpermAnalyser (Hamilton) was used tomeasure the sperm count
and percentage motility.
Cell Counting for Spermatids
For histological analyses, Bouin’s fixed, paraffin embedded tissue
sections were stained with H&E. Testicular cell composition was
estimated using standard stereological techniques involving point
counting of cell nuclei to determine the nuclear volume per
testis of round, elongated and total spermatids, as previously
described (Welsh et al., 2009). In brief, cross sections of testis
were examined using 63× objective fitted to Zeiss AxioScope
A1 and a 121-point eyepiece graticule (Leica Microsystems,
Wetzlar, Germany). Applying a systematic sampling pattern from
a random starting point, 32 microscopic fields (3872 points) were
counted for each animal. Points falling over Sertoli cell or germ
cell nuclei, seminiferous epithelium, interstitium, seminiferous
tubule lumen were scored, and they were expressed as relative
(%) volume per testis. For round, elongated and total spermatids,
the values for percent nuclear volume were converted to absolute
nuclear volumes per testis by reference to testis volume (weight)
because shrinkage was minimal. The results were represented as
percentage change in DMA groups compared to the PBS group.
Statistical Analysis: Statistical analyses was performed with
GraphPad Prism 7. Results were expressed as the mean ± SD and
were compared by Student’s t-test. All results with p < 0.05 were
considered significant.
RESULTS
DMA Reversibly Influences the
Reproductive Parameters
Previously we have shown that DMA treatment causes significant
changes in reproductive parameters by decreasing the spermatid
counts (Khera et al., 2020). To determine whether DMA
discontinuation could reverse these parameters, we performed
another independent experiment. Eight male rats were treated
with either PBS or DMA for 8 weeks after which three animals
per group were sacrificed to ensure that the reproductive
parameters were decreasing as previously reported (Khera et al.,
2020). The other five animals were kept without any further
injections. The animals that were sacrificed after 8 weeks of DMA
treatment showed a significant decrease in testis and epididymis
weight. Moreover, distortions in seminiferous tubules and a
reduced sperm count and motility were observed. A concomitant
distortion of epididymal histology was evident (Figure 1D). All
these results on reproductive parameters (Figure 1) confirmed
the negative effect of DMA on reproductive parameters of
animals as previously reported (Khera et al., 2020).
The other five animals were then housed for the next 8 weeks
without any further treatment. At the end of 16 weeks (8 weeks
of injections and 8 weeks of no injections) the animals were
sacrificed, and their reproductive parameters analyzed. There
was no significant difference in the testis weight and the
area of seminiferous tubules comparing DMA recovery (where
DMA treatment was stopped) and PBS controls (Figures 2A,B).
Moreover, the seminiferous epithelium of animals from the
DMA recovery group was indistinguishable from that of PBS
controls (Figure 2C). The level of gene expression of markers for
spermatogonia (plzf), spermatocyte (aurkc, plk1) and spermatids
(tnp1, tnp2, prm1, prm2, pcsk4, odf1) was in the same range
and insignificantly different for DMA recovery and PBS treated
groups (Figure 2D). Previously, without a recovery phase of
8 weeks, DMA treatment lead to a significant decrease in
the number of elongated and total spermatids (Khera et al.,
2020). Next, we did the cell counting for round, elongated and
total spermatids for DMA recovery and PBS groups. Germ cell
counting results showed no differences in number of spermatids
thus confirming that testicular features returned to normalcy
after stopping the DMA treatment for 8 weeks (Figures 2E–G).
Since testicular functions appeared completely normal, we
next wanted to see the effect of stopping the DMA treatment
on the epididymal parameters. Epididymal weight and histology
was indistinguishable in both the groups (Figures 3A,B). No
significant changes were observed in sperm count and motility
(Figures 3C,D and Supplementary videos, Video 1: PBS, Video
2: DMA Recovery). Moreover, no significant changes were
observed in any of the computer assisted sperm analysis (CASA)
parameters listed in Table 1.
DMA Causes Infertility in Rats
Since 8 weeks of recovery from DMA treatment was able to
reverse the damaging effect on reproductive parameters, we
further determined the effect of DMA treatment on fertility
of male rats. For this, we treated a new set of male rats with
PBS or DMA (once/week) for a period of 8 weeks and then
subjected these animals to a mating experiment during which
one treated male was caged with one untreated female. The
injections were continued during the mating experiments and
pups were analyzed at subsequent time intervals. After a period
of three weeks of breeding, all six PBS-treated animals sired
litters. However, in the DMA treated group, three animals sired
litters and the other three did not. We, therefore, regrouped the
DMA treated animals according to sensitivity, where group 1
comprised of animals sensitive to 8 weeks of once per week DMA
treatment (i.e., siring no litters) and group 2 consisting of animals
insensitive to 8 weeks of once per week DMA treatment (i.e., still
fertile). The six PBS controls, who sired litters, were randomly
distributed into the two groups (3 PBS animals in group 1 and 3
PBS animal in group 2) (Figure 4).
During the following 3 and 6 weeks of continuing once per
week DMA treatment, group 1 animals appeared to be sterile
since the females caged with the DMA treated animals did not
produce pups (Figure 5A).
For group 2, we then increased DMA treatment to twice
a week and continued mating. After increasing the injection
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FIGURE 1 | Effect of DMA versus PBA treatment on reproductive parameters (n = 3). Effect of DMA treatment on (A) testis weight, (B) area of seminiferous tubules,
and (C) epididymis weight. (D) Histological analysis of testicular sections. Arrow indicated empty seminiferous tubule lumen (scale bar = 100 µm). (E) Histological
analysis of the Epididymis. Arrow indicates absence of sperm (scale bar = 100µm). (F) Sperm count and (G) percentage motility of PBS and DMA treated animals.
Data represents mean ± SD (*p < 0.05, **p < 0.01, obtained by two tailed student t-test).
frequency to twice a week over a period of 3 weeks, the animals
of group 2 turned completely infertile for the next six weeks,
where they were housed with female rats (Figure 5B). Therefore,
Group 2 animals were characterized to be completely infertile
during 6 weeks of twice/week treatment. Thus, depending on
individual variability of each of the DMA treated males, a
complete contraceptive effect can be reached in rats in a DMA
concentration dependent manner.
DMA Causes Reversible Infertility in Rats
To examine the reversibility of DMA induced contraception,
we assessed if fertility was restored upon cessation of DMA
treatment. For both, Group 1 and Group 2, the fertility was
regained 8 weeks after stopping the once or twice a week
DMA treatment. The pups born in both the groups were, in
terms of number, statistically similar to ones born from PBS
treated control animals (Figure 6). The offspring appeared to be
morphologically similar in both groups and developed normally
for one week of their life. No abnormalities were observed in
the major organs like brain, liver and heart as examined by MRI
analysis (Supplementary Figure 1).
Effect of Stopping the DMA Treatment of
Hormonal Levels
Our previous data has shown that DMA treatment had no
effect on levels of sexual hormones (Khera et al., 2020). To
study if stopping DMA treatment maintained hormone levels, we
analyzed the serum levels of testosterone, follicular stimulating
hormone (FSH) and luteinizing hormone (LH) and found no
significant changes in the hormonal levels after stopping DMA
treatment (Figure 7).
DISCUSSION
Development of a reversible, non-hormonal and safe male
contraceptive remains a challenge. The major reason for this
lies in the physiological differences in the male and female
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FIGURE 2 | Effect of stopping DMA treatment on reproductive parameters. Effect of stopping the DMA treatment on (A) testis weight (n = 5) and (B) area of
seminiferous tubules (n = 3). (C) Histological analysis of testicular sections (n = 3). Arrows indicate normal seminiferous tubule lumen in both PBS and DMA recovery
groups (scale bar = 100 µm). (D) Quantitative RT-PCR analysis of genes expressed at different stages of sperm maturation (n = 3). Percentage of (E) round
spermatids, (F) elongated spermatids, and (G) total spermatids in DMA recovery group compared to the PBS group (n = 3). Data represents mean ± SD.
FIGURE 3 | Effect of stopping the DMA treatment on epididymal parameters. (A) Epididymis weight (n = 5). (B) Histological analysis of the Epididymis (scale
bar = 100 µm) (n = 3) (C) sperm count and (D) percentage motility of PBS and DMA Recovery group animals (n = 5). Data represents mean ± SD.
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TABLE 1 | Measurement of CASA parameters in epididymal sperm of PBS and
DMA Recovery groups.
Parameter PBS DMA Recovery
Path velocity VAP µm/s 165.68 ± 15.4 173.08 ± 13.6
Prog. velocity VSL µm/s 106.82 ± 13.97 112.94 ± 12.0
Track speed VCL µm/s 334.68 ± 23.3 340.22 ± 25.5
Lateral amplitude ALH µm 16.8 ± 1.15 16.48 ± 1.90
Beat frequency BCF Hz 28.5 ± 1.50 26.84 ± 3.26
Straightness STR % 62.67 ± 3.50 62.6 ± 3.31
Linearity LIN % 34.16 ± 1.94 35 ± 3.90
Elongation % 25.34 ± 2.87 25.4 ± 4.71
Area µm sq 242.93 ± 67.95 199.54 ± 63.06
Data represent mean ± SD (n = 5).
reproductive systems. A female contraceptive should suppress
the fertilization of one ovum per menstrual cycle. In contrast, a
male contraceptive has the obligation of blocking 15–200 million
sperms/mL of ejaculate. Moreover, the spermatogenesis cycle
lasts for 74 days, therefore, contraceptives should be regularly
given for a period of at least 5–8 weeks before a wanted
contraceptive state can be reached (Griswold, 2016). Although
female contraceptives are very effective at preventing unintended
pregnancies, many women cannot use them because of various
side effects or health conditions (National Research Council
Committee on Population, 1989).
Previous studies from our lab and the current study has
focused on the use of DMA as a non-hormonal and reversible
male contraceptive agent in rats. Administration of DMA once
a week for 8 weeks (equivalent to one spermatogenic cycle in
rats) negatively affects the reproductive parameters. Additional
injections for 3 weeks for DMA sensitive rats (Group 1) or a
further increased frequency for insensitive rats (Group 2) lead to
complete infertility in rats with no pups being born. In addition,
no changes were found in the sexual behavior of the treated rats,
which was also confirmed by the absence of changes in serum
testosterone levels. Moreover, vaginal smear experiments showed
the presence of spermatozoa even when no pups were being born
(Supplementary Figure 2).
The effect of DMA is completely reversible as pups were born
eight weeks after stopping the treatment in both the experimental
groups (Group1 and Group2) where once or twice a week
treatment with DMA was initially needed for male sterility. The
FIGURE 4 | Diagrammatic representation of breeding experiments. Three weeks after the start of breeding, Group 1 animals received either PBS or DMA injections
once/week. Group 2 animals received either PBS or DMA injections twice/week. 6 PBS animals were randomly divided into three each for group 1 and group 2.
FIGURE 5 | Number of pups born during DMA treatment. (A) Number of pups born per animal in PBS and DMA treated animals after 8 weeks of initial treatment
plus 6 weeks of continuing treatment while breeding: Group1 (n = 3). (B) Number of pups born per animal in PBS and DMA treated animals after 8 weeks of initial
treatment plus 3 weeks of once per week plus 6 weeks of twice per week continuing treatment while breeding: Group2 (n = 3). Data represents mean ± SD
(**p < 0.01, obtained by two tailed student t-test).
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FIGURE 6 | Number of pups born after stopping DMA treatment. Number of pups born per animal in PBS and DMA treated animals after 3, 6, and 8 weeks of
stopping the treatment (n = 3). (A) Diagrammatic representation of experimental protocol: Group 1. (B) The animals that showed complete infertility at a dose for
once/week DMA treatment, produced pups 8 weeks after the treatment was stopped: Group1 (n = 3). (C) Diagrammatic representation of experimental protocol:
Group 2. (D) The animals that showed complete infertility after escalating the dose to twice per week showed complete fertility after 8 weeks of stopping the DMA
treatment: Group2 (n = 3). Data represents mean ± SD (**p < 0.01, obtained by two tailed student t-test).
FIGURE 7 | Serological analysis of hormonal levels. (A) Serum FSH, (B) serum LH, and (C) serum testosterone levels in PBS and DMA recovery groups (n = 3). Data
represents mean ± SD.
gestation period in rats is three weeks and since pups were
born after 8 weeks of stopping the treatment, implied that the
females were pregnant after 5 weeks of stopping the treatment.
These results were also consistent with the fact that DMA affects
the post meiotic stages of spermatogenesis. We also observed
spermatozoa in the vagina of female rats in a vaginal smear
experiment, five weeks after starting the mating experiments
(Supplementary Figure 2). Thus, DMA acts in a post-meiotic
manner to achieve reversible contraception in rats.
Previously, Bromodomain inhibitors with very high affinity
to BET proteins, like JQ1, have been used to achieve male
contraception in mice. Its male contraceptive effect was
attributed to the inhibition of the testis specific BRDT protein
(Matzuk et al., 2012). BRDT is expressed during pachytene
spermatocyte, diplotene spermatocyte, and round spermatid
stages (Shang et al., 2007). Although JQ1 shows promising
results, further research has revealed that JQ1 is not well
tolerated in mice. At higher doses, JQ1 causes significant
decrease in body weight (Lee et al., 2016). Our results
show that DMA treatment and recovery does not alter the
body weights of animals compared to the PBS controls
(Supplementary Figure 3). Since JQ1 causes severe side effects,
other BET inhibitors must be designed specifically for male
contraception. In contrast to JQ1, DMA is a low affinity
bromodomain inhibitor (Ghayor et al., 2017) and is well tolerated
in humans, and therefore used as FDA approved excipient.
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DMA has no effect on the number of spermatocytes or round
spermatids within the seminiferous tubules, where BRDT is
expressed (Khera et al., 2020). It appears to target mainly
spermiogenesis, which is more dependent on BRD4 expression,
indicated by compromised acrosomal structure, decreased
number and gene expression for markers of total and elongated
spermatids (tnp1, tnp2, prm1, prm2, pcsk4, and odf1) (Khera
et al., 2020). This suggests that on the molecular level, male
sterility by DMA acts via inhibition of BRD4 and not via BRDT,
the main target of JQ1 in this concept.
In humans, DMA is injected as a drug solubilizer, e.g., to
facilitate busulfan treatment in children during chemotherapy.
The total concentration of DMA administered per regimen in
a patient can be up to 105 mmoL (Oechtering et al., 2006;
Trame et al., 2013). Data from children receiving the busulfan
formulation with DMA revealed that DMA is not toxic since it
is rapidly cleared from the body. Taken together these results
indicate that DMA is safe for use in humans (Hempel et al., 2007).
We observed no signs of toxicity as was evident by normal hepatic
architecture of liver sections from PBS and DMA treated animals
(Supplementary Figure 4). The current study showed DMA acts
as a reversible and non-hormonal contraceptive for rats in a
dose dependent manner. Since bromodomains are evolutionary
conserved (Muller et al., 2011), DMA can act as a potential
male contraceptive for humans. However, more research should
be focused on finding the right concentration and a feasible
application mode for human use.
DMA has very good skin penetration property. It has been
used as a solvent for enhancing the penetration of compounds
through the skin (Zhang et al., 2015). Therefore, future studies
should be directed toward examining the contraceptive effect of
DMA if applied with a topical gel. In the end, further research
can lead to an improved application of DMA e.g., in the form of
a slow release drug delivery DMA-depot patch.
Instead of developing a new molecule for male contraception,
in the current study, we have repurposed the use of DMA
that is already used as a solvent to administer drugs in
humans. Taken together, our results show that DMA acts in a
non-hormonal, post-meiotic and reversible manner to achieve
reversible contraception in rats.
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